{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T09:06:57Z","timestamp":1784020017390,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy (NAC) is commonly used in early-stage breast cancer. A complete pathologic response (pCR) after NAC is associated with improved outcomes. This study investigated differences in pCR and clinical outcomes by race.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-institution, retrospective chart review identified patients with early-stage breast cancer who received NAC between January 1, 2010, and December 31, 2017. Associations between race and pathologic and clinical outcomes were evaluated using multivariable logistic regression and Cox proportional hazard models. Kaplan\u2013Meier estimates and log rank tests assessed differences in recurrence-free survival (RFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 532 patients with breast cancer of all receptor subtypes were identified; 323 (60.7%) White, 188 (35.3%) Black and 21 (3.9%) other\/unknown. The pCR rate was different between the 3 race categories; White 27.2%, Black 19.1% and other\/unknown 9.5% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03). In multivariate analysis, pCR rates were higher in White versus Black patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02). Patients with triple-negative disease demonstrated the largest difference in pCR (White 44.3% versus Black 27.1%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04). Black patients had inferior OS compared to White patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03). There was no difference in RFS by race (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.07).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Black patients demonstrated a lower pCR rate compared to White patients, and this was more pronounced in the triple-negative subgroup. There was no difference in RFS by race, but OS was inferior among Black patients. It is possible that the lower pCR rate in Black patients may contribute to lower OS; however, more investigation is needed to explain these differences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-026-07972-y","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:43:17Z","timestamp":1777956197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Racial differences in pathologic complete response rate and clinical outcomes following neoadjuvant chemotherapy for breast cancer"],"prefix":"10.1007","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5374-0411","authenticated-orcid":false,"given":"Ashley","family":"Matusz-Fisher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Livasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla","family":"Hadzikadic-Gusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley Y.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Wallander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Neelands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhvani","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle L.","family":"Heeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette R.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Richard L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"7972_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"7972_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/canjclin.54.2.78","volume":"54","author":"E Ward","year":"2004","unstructured":"Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A et al (2004) Cancer disparities by race\/ethnicity and socioeconomic status. CA Cancer J Clin 54:78\u201393. https:\/\/doi.org\/10.3322\/canjclin.54.2.78","journal-title":"CA Cancer J Clin"},{"key":"7972_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/jnci\/94.7.490","volume":"94","author":"CJ Bradley","year":"2002","unstructured":"Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94:490\u2013496. https:\/\/doi.org\/10.1093\/jnci\/94.7.490","journal-title":"J Natl Cancer Inst"},{"key":"7972_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3322\/caac.21718","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL (2022) Cancer statistics for African American\/Black people 2022. CA Cancer J Clin 72:202\u2013229. https:\/\/doi.org\/10.3322\/caac.21718","journal-title":"CA Cancer J Clin"},{"key":"7972_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1200\/JCO.23.01199","volume":"42","author":"HE Woriax","year":"2024","unstructured":"Woriax HE, Thomas SM, Plichta JK, Rosenberger LH, Botty van den Bruele A, Chiba A et al (2024) Racial\/ethnic disparities in pathologic complete response and overall survival in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 42:1635\u20131645. https:\/\/doi.org\/10.1200\/JCO.23.01199","journal-title":"J Clin Oncol"},{"key":"7972_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10549-023-06943-x","volume":"200","author":"E Terman","year":"2023","unstructured":"Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J et al (2023) The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat 200:75\u201383. https:\/\/doi.org\/10.1007\/s10549-023-06943-x","journal-title":"Breast Cancer Res Treat"},{"key":"7972_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74:477\u2013495. https:\/\/doi.org\/10.3322\/caac.21863","journal-title":"CA Cancer J Clin"},{"key":"7972_CR8","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429\u20134434. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045","journal-title":"Clin Cancer Res"},{"key":"7972_CR9","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938\u20131948. https:\/\/doi.org\/10.1056\/NEJMra1001389","journal-title":"N Engl J Med"},{"key":"7972_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.3329","volume":"6","author":"F Zhao","year":"2023","unstructured":"Zhao F, Miyashita M, Hattori M, Yoshimatsu T, Howard F, Kaneva K et al (2023) Racial disparities in pathological complete response among patients receiving neoadjuvant chemotherapy for early-stage breast cancer. JAMA Netw Open 6:e233329. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.3329","journal-title":"JAMA Netw Open"},{"key":"7972_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrc3896","volume":"15","author":"EC Dietze","year":"2015","unstructured":"Dietze EC, Sistrunk C, Miranda-Carboni G, O\u2019Regan R, Seewaldt VL (2015) Triple-negative breast cancer in African-American women: disparities versus biology. Nat Rev Cancer 15:248\u2013254. https:\/\/doi.org\/10.1038\/nrc3896","journal-title":"Nat Rev Cancer"},{"key":"7972_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/jncimonographs\/lgv004","volume":"2015","author":"DF Hayes","year":"2015","unstructured":"Hayes DF, Schott AF (2015) Neoadjuvant chemotherapy: what are the benefits for the patient and for the investigator? J Natl Cancer Inst Monogr 2015:36\u201339. https:\/\/doi.org\/10.1093\/jncimonographs\/lgv004","journal-title":"J Natl Cancer Inst Monogr"},{"key":"7972_CR13","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1245\/s10434-022-12300-x","volume":"29","author":"EA Elder","year":"2022","unstructured":"Elder EA, Livasy CA, Donahue EE, Neelands B, Patrick A, Needham M et al (2022) Residual cancer burden class associated with survival outcomes in women with different phenotypic subtypes of breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol 29:8060\u20138069. https:\/\/doi.org\/10.1245\/s10434-022-12300-x","journal-title":"Ann Surg Oncol"},{"key":"7972_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.6004\/jnccn.2017.0158","volume":"15","author":"L Spring","year":"2017","unstructured":"Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R et al (2017) Pathologic complete response after neoadjuvant chemotherapy and long-term outcomes among young women with breast cancer. J Natl Compr Canc Netw 15:1216\u20131223. https:\/\/doi.org\/10.6004\/jnccn.2017.0158","journal-title":"J Natl Compr Canc Netw"},{"key":"7972_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","volume":"35","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M et al (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 35:1049\u20131060. https:\/\/doi.org\/10.1200\/JCO.2015.63.1010","journal-title":"J Clin Oncol"},{"key":"7972_CR16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/jco.2011.38.8595","volume":"30","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796\u20131804. https:\/\/doi.org\/10.1200\/jco.2011.38.8595","journal-title":"J Clin Oncol"},{"key":"7972_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.6004\/jnccn.2020.7550","volume":"18","author":"M Huang","year":"2020","unstructured":"Huang M, O\u2019Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S et al (2020) Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer. J Natl Compr Cancer Netw 18:1096\u20131104. https:\/\/doi.org\/10.6004\/jnccn.2020.7550","journal-title":"J Natl Compr Cancer Netw"},{"key":"7972_CR18","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.1245\/s10434-022-12038-6","volume":"29","author":"CV Pestana","year":"2022","unstructured":"Pestana CV, Livasy CA, Donahue EE, Neelands B, Tan AR, Sarantou T et al (2022) Does residual cancer burden predict local recurrence after neoadjuvant chemotherapy? Ann Surg Oncol 29:7716\u20137724. https:\/\/doi.org\/10.1245\/s10434-022-12038-6","journal-title":"Ann Surg Oncol"},{"key":"7972_CR19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172. https:\/\/doi.org\/10.1016\/s0140-6736(13)62422-8","journal-title":"Lancet"},{"key":"7972_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s1470-2045(21)00589-1","volume":"23","author":"C Yau","year":"2022","unstructured":"Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D et al (2022) Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 23:149\u2013160. https:\/\/doi.org\/10.1016\/s1470-2045(21)00589-1","journal-title":"Lancet Oncol"},{"key":"7972_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"7972_CR22","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/jco.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, Hasm\u00fcller S, Lebeau A, Kreienberg R et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2\u2013overexpressing breast cancer: results from the techno trial of the AGO and GBG study groups. J Clin Oncol 29:3351\u20133357. https:\/\/doi.org\/10.1200\/jco.2010.31.4930","journal-title":"J Clin Oncol"},{"key":"7972_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115\u2013126. https:\/\/doi.org\/10.1016\/s1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"key":"7972_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","volume":"36","author":"LA Huppert","year":"2025","unstructured":"Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C et al (2025) Pathologic complete response (pCR) rates for patients with HR+\/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann Oncol 36:172\u2013184. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.018","journal-title":"Ann Oncol"},{"key":"7972_CR25","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1002\/cncr.25296","volume":"116","author":"M Chavez-Macgregor","year":"2010","unstructured":"Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC et al (2010) Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race\/ethnicity. Cancer 116:4168\u20134177. https:\/\/doi.org\/10.1002\/cncr.25296","journal-title":"Cancer"},{"key":"7972_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-015-3350-2","volume":"150","author":"JR Tichy","year":"2015","unstructured":"Tichy JR, Deal AM, Anders CK, Reeder-Hayes K, Carey LA (2015) Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat 150:667\u2013674. https:\/\/doi.org\/10.1007\/s10549-015-3350-2","journal-title":"Breast Cancer Res Treat"},{"key":"7972_CR27","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/jco.2015.63.7801","volume":"33","author":"BK Killelea","year":"2015","unstructured":"Killelea BK, Yang VQ, Wang S-Y, Hayse B, Mougalian S, Horowitz NR et al (2015) Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the National Cancer Data Base. J Clin Oncol 33:4267\u20134276. https:\/\/doi.org\/10.1200\/jco.2015.63.7801","journal-title":"J Clin Oncol"},{"key":"7972_CR28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.49646","volume":"6","author":"B Kyalwazi","year":"2023","unstructured":"Kyalwazi B, Yau C, Campbell MJ, Yoshimatsu TF, Chien AJ, Wallace AM et al (2023) Race, gene expression signatures, and clinical outcomes of patients with high-risk early breast cancer. JAMA Netw Open 6:e2349646. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.49646","journal-title":"JAMA Netw Open"},{"key":"7972_CR29","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7755.Disp24-c035","volume":"33","author":"JQ Freeman","year":"2024","unstructured":"Freeman JQ, Huo D, Shubeck SP, Chen N, Yarlagadda SR, Nanda R et al (2024) Abstract C035: Immunotherapy for triple-negative breast cancer in the US: national trends, racial\/ethnic disparities, and oncologic outcomes. Cancer Epidemiol Biomark Prev 33:C035-C035. https:\/\/doi.org\/10.1158\/1538-7755.Disp24-c035","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"7972_CR30","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/jco.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol 38:1346\u20131366. https:\/\/doi.org\/10.1200\/jco.19.02309","journal-title":"J Clin Oncol"},{"key":"7972_CR31","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/jco.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"7972_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27093-y","volume":"12","author":"AE Smith","year":"2021","unstructured":"Smith AE, Ferraro E, Safonov A, Morales CB, Lahuerta EJA, Li Q et al (2021) HER2\u2009+\u2009breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nat Commun 12:6667. https:\/\/doi.org\/10.1038\/s41467-021-27093-y","journal-title":"Nat Commun"},{"key":"7972_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.5834","volume":"6","author":"S Shubeck","year":"2023","unstructured":"Shubeck S, Zhao F, Howard FM, Olopade OI, Huo D (2023) Response to treatment, racial and ethnic disparity, and survival in patients with breast cancer undergoing neoadjuvant chemotherapy in the US. JAMA Netw Open 6:e235834-e235834. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.5834","journal-title":"JAMA Netw Open"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07972-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:30:16Z","timestamp":1784017816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07972-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7972"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07972-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"This study was approved by the Atrium Health Institutional Review Board (IRB 00083102). A Waiver of Informed Consent and Waiver of HIPAA Authorization were granted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"29"}}